"Tuberous Sclerosis/drug therapy"[MAJR] - Search Results

Year	Number of Results
1977	1
1985	1
1986	1
1988	1
1991	1
1997	2
1998	1
1999	2
2000	1
2001	1
2003	1
2004	2
2005	2
2006	4
2007	3
2008	11
2009	8
2010	11
2011	11
2012	15
2013	19
2014	19
2015	29
2016	24
2017	16
2018	25
2019	26
2020	23
2021	27
2022	31
2023	31
2024	13

1

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.

Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, O'Callaghan FJ, Wong M, Sahebkar F, Checketts D, Knappertz V; GWPCARE6 Study Group. Thiele EA, et al. JAMA Neurol. 2021 Mar 1;78(3):285-292. doi: 10.1001/jamaneurol.2020.4607. JAMA Neurol. 2021. PMID: 33346789 Free PMC article. Clinical Trial.

2

Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy.

Curatolo P, Specchio N, Aronica E. Curatolo P, et al. Lancet Neurol. 2022 Sep;21(9):843-856. doi: 10.1016/S1474-4422(22)00213-7. Lancet Neurol. 2022. PMID: 35963265 Review.

3

Current and future pharmacotherapy options for drug-resistant epilepsy.

Elkommos S, Mula M. Elkommos S, et al. Expert Opin Pharmacother. 2022 Dec;23(18):2023-2034. doi: 10.1080/14656566.2022.2128670. Epub 2022 Sep 27. Expert Opin Pharmacother. 2022. PMID: 36154780 Review.

4

Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non-small cell lung cancer.

Huang Q, Li F, Hu H, Fang Z, Gao Z, Xia G, Ng WL, Khodadadi-Jamayran A, Chen T, Deng J, Zhang H, Almonte C, Labbe K, Han H, Geng K, Tang S, Freeman GJ, Li Y, Chen H, Wong KK. Huang Q, et al. Sci Adv. 2022 Feb 4;8(5):eabi9533. doi: 10.1126/sciadv.abi9533. Epub 2022 Feb 4. Sci Adv. 2022. PMID: 35119931 Free PMC article.

5

mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex.

Franz DN, Krueger DA. Franz DN, et al. Am J Med Genet C Semin Med Genet. 2018 Sep;178(3):365-373. doi: 10.1002/ajmg.c.31655. Epub 2018 Oct 11. Am J Med Genet C Semin Med Genet. 2018. PMID: 30307123 Review.

6

Predicting Drug Treatment Outcomes in Childrens with Tuberous Sclerosis Complex-Related Epilepsy: A Clinical Radiomics Study.

Hu Z, Jiang D, Zhao X, Yang J, Liang D, Wang H, Zhao C, Liao J. Hu Z, et al. AJNR Am J Neuroradiol. 2023 Jul;44(7):853-860. doi: 10.3174/ajnr.A7911. Epub 2023 Jun 22. AJNR Am J Neuroradiol. 2023. PMID: 37348968

7

Paradigm shift in the treatment of tuberous sclerosis: Effectiveness of everolimus.

Previtali R, Prontera G, Alfei E, Nespoli L, Masnada S, Veggiotti P, Mannarino S. Previtali R, et al. Pharmacol Res. 2023 Sep;195:106884. doi: 10.1016/j.phrs.2023.106884. Epub 2023 Aug 6. Pharmacol Res. 2023. PMID: 37549757 Free article. Review.

8

Stiripentol for Drug-Resistant Epilepsy Treatment in Tuberous Sclerosis Complex.

Aungaroon G, Mehta A, Horn PS, Franz DN. Aungaroon G, et al. Pediatr Neurol. 2023 Feb;139:86-92. doi: 10.1016/j.pediatrneurol.2022.11.017. Epub 2022 Nov 29. Pediatr Neurol. 2023. PMID: 36586162

9

Renal disease in tuberous sclerosis complex: pathogenesis and therapy.

Lam HC, Siroky BJ, Henske EP. Lam HC, et al. Nat Rev Nephrol. 2018 Nov;14(11):704-716. doi: 10.1038/s41581-018-0059-6. Nat Rev Nephrol. 2018. PMID: 30232410 Review.

10

Kinase Inhibitors in Genetic Diseases.

D'Antona L, Amato R, Brescia C, Rocca V, Colao E, Iuliano R, Blazer-Yost BL, Perrotti N. D'Antona L, et al. Int J Mol Sci. 2023 Mar 9;24(6):5276. doi: 10.3390/ijms24065276. Int J Mol Sci. 2023. PMID: 36982349 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

314 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

314 results

Results by year